NCT01959269View on ClinicalTrials.gov

Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy

CompletedOBSERVATIONAL
Enrollment

483

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

March 31, 2017

Study Completion Date

July 7, 2017

Conditions
Colorectal Neoplasm
Interventions
DRUG

Regorafenib (Stivarga, BAY 73-4506)

As determined by the treating physician

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01959269 - Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy | Biotech Hunter | Biotech Hunter